According to the European Medicines Agency(EMA), the use of blinatumomab in the pediatric population is limited to children aged one or older with Philadelphia chromosome-negative CD19-positive B-cell precursor ALL (CD19+ R/R Ph-negative BCP-ALL), which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior HSCT, or in high-risk first relapse as part of consolidation therapy [73]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.